As of 14 Oct 2026, EpiBiologics has raised $107M across 1 verified round on record; latest: $107 million Series B led by GV (Google Ventures) and Johnson & Johnson, announced 8 Jan 2026.
They develop bispecific antibodies designed to selectively degrade disease-causing extracellular proteins.
epibiologics.comLinkedInBiotech
1 source
The source says the round included 10 other investors but names only three.
Published by hand (biopharmadive.com): "EpiBiologics, a biotechnology startup developing protein degraders for cancer and immune diseases, has raised $107 million in funding to advance its lead program into the clinic.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $107M | 2026-01-08 | GV (Google Ventures), Johnson & Johnson | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The source says the round included 10 other investors but names only three. Published by hand (biopharmadive.com): "EpiBiologics, a biotechnology startup developing protein degraders for cancer and immune diseases, has raised $107 million in funding to advance its lead program into the clinic.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it | ||||